Report

TABLE OF CONTENTS
1 INTRODUCTION 82
1.1 OBJECTIVES OF THE STUDY 82
1.2 MARKET DEFINITION 82
1.3 OVERVIEW OF ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET 82
1.4 LIMITATIONS 84
1.5 MARKETS COVERED 85
2 MARKET SEGMENTATION 87
2.1 MARKETS COVERED 87
2.2 GEOGRAPHICAL SCOPE 88
2.3 YEARS CONSIDERED FOR THE STUDY 89
2.4 CURRENCY AND PRICING 89
2.5 DBMR TRIPOD DATA VALIDATION MODEL 90
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 93
2.7 MULTIVARIATE MODELLING 94
2.8 DBMR MARKET POSITION GRID 95
2.9 VENDOR SHARE ANALYSIS 96
2.10 MARKET END-USER COVERAGE GRID 97
2.11 SECONDARY SOURCES 98
2.12 ASSUMPTIONS 98
3 EXECUTIVE SUMMARY 99
4 PREMIUM INSIGHTS 105
4.1 PORTERS FIVE FORCES ANALYSIS 106
4.2 BRAND OUTLOOK 107
4.2.1 BRAND COMPARATIVE ANALYSIS OF KEY ASIA-PACIFIC PLAYERS 107
4.2.1.1 BRAND COMPARATIVE NARRATIVE (ANALYTICAL OVERVIEW) 108
4.2.2 PRODUCT VS BRAND OVERVIEW - ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET 109
4.2.2.1 PRODUCT OVERVIEW - ENDOSCOPIC HEMOSTASIS DEVICES 109
4.2.2.2 BRAND OVERVIEW - INFLUENCE ON ASIA-PACIFIC CLINICAL ADOPTION 109
4.3 CONSUMER BUYING BEHAVIOUR 110
4.3.1 CLINICAL EFFECTIVENESS AND PATIENT OUTCOMES 110
4.3.2 COST AND VALUE CONSIDERATIONS 110
4.3.3 COMPATIBILITY AND INTEGRATION 110
4.3.4 TRAINING REQUIREMENTS AND EASE OF USE 110
4.3.5 REIMBURSEMENT AND HEALTHCARE POLICY ALIGNMENT 110
4.3.6 PROCUREMENT PROCESSES AND BULK AGREEMENTS 111
4.3.7 INFLUENCE OF CLINICAL STAKEHOLDERS 111
4.3.8 TRENDS IN BUYER BEHAVIOUR 111
4.3.9 CONCLUSION 111
4.4 PATENT ANALYSIS 112
4.4.1 PATENT QUALITY AND STRENGTH - ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET 112
4.4.2 COUNTRY PATENT LANDSCAPE 112
4.4.3 IP STRATEGY AND MANAGEMENT 114
4.4.4 LICENSING AND COLLABORATION 114
4.5 RAW MATERIAL COVERAGE 116
4.5.1 METALLIC COMPONENTS AND ALLOY SYSTEMS 116
4.5.2 POLYMERIC AND SYNTHETIC MATERIALS 116
4.5.3 NATURAL AND BIOCOMPATIBLE MATERIALS 116
4.5.4 ELECTRICAL AND THERMAL MATERIAL SYSTEMS 117
4.5.5 EXPENDABLE ACCESSORIES AND SINGLE-USE MATERIALS 117
4.6 TECHNOLOGICAL ADVANCEMENTS IN ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET 118
4.6.1 ENHANCED MECHANICAL HEMOSTASIS TOOLS 118
4.6.2 ADVANCED THERMAL COAGULATION AND ENERGY-BASED SYSTEMS 118
4.6.3 NOVEL TOPICAL HEMOSTATIC AGENTS 118
4.6.4 INTEGRATION WITH ADJUNCTIVE DIAGNOSTIC TECHNOLOGIES 118
4.6.5 DEVELOPMENT OF MULTIFUNCTIONAL AND COMBINATION DEVICES 118
4.6.6 IMPROVED USER ERGONOMICS AND DEVICE DEPLOYMENT SYSTEMS 119
4.6.7 CONCLUSION 119
4.7 VALUE CHAIN ANALYSIS 120
4.7.1 OVERVIEW 120
4.7.2 RAW MATERIALS & COMPONENTS 120
4.7.3 DEVICE DESIGN, R&D & MANUFACTURING 121
4.7.4 PROCESSING, FINISHING & STERILIZATION 121
4.7.5 PACKAGING & LABELING 121
4.7.6 LOGISTICS, DISTRIBUTION & COMMERCIALIZATION 121
4.7.7 CONCLUSION 121
4.8 VENDOR SELECTION CRITERIA 122
4.8.1 CLINICAL PERFORMANCE 122
4.8.2 REGULATORY COMPLIANCE AND APPROVALS 122
4.8.3 COST AND TOTAL VALUE PROPOSITION 122
4.8.4 SUPPLY CHAIN ROBUSTNESS AND LOGISTICS 122
4.8.5 SUPPORT, TRAINING AND CLINICAL EDUCATION 122
4.8.6 QUALITY SYSTEMS AND REPROCESSING GUIDANCE 122
4.8.7 REPUTATION, PEER ACCEPTANCE AND POST-MARKET PERFORMANCE 122
4.8.8 INNOVATION AND FUTURE-READINESS 123
4.9 COMPANY EVALUATION QUADRANT 124
4.10 PROFIT MARGIN SCENARIO 126
4.10.1 MARGIN IMPROVEMENT DRIVERS 126
4.10.2 COST PRESSURE 126
4.10.3 REGIONAL VARIATIONS 126
4.10.4 FUTURE SCENARIOS 127
4.11 CLIMATE CHANGE SCENARIO 128
4.11.1 ENVIRONMENTAL CONCERNS 128
4.11.2 INDUSTRY RESPONSE 128
4.11.3 GOVERNMENT'S ROLE 128
4.11.4 ANALYST RECOMMENDATIONS 129
4.12 INNOVATION TRACKER AND STRATEGIC ANALYSIS 130
4.12.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS 130
4.12.1.1 JOINT VENTURES 130
4.12.1.2 MERGERS AND ACQUISITIONS 130
4.12.1.3 LICENSING AND PARTNERSHIP 130
4.12.1.4 TECHNOLOGY COLLABORATIONS 130
4.12.2 STRATEGIC DIVESTMENTS 131
4.12.3 STAGE OF DEVELOPMENT 131
4.12.4 TIMELINES AND MILESTONES 131
4.12.5 INNOVATION STRATEGIES AND METHODOLOGIES 131
4.12.6 RISK ASSESSMENT AND MITIGATION 131
4.12.7 FUTURE OUTLOOK 132
4.13 PRICING ANALYSIS 133
4.13.1 HEMOSTATIC CLIPS AND FORCEPS PRICING 133
4.13.2 BANDING AND COAGULATION DEVICES 134
4.13.3 REGULATORY AND REIMBURSEMENT IMPACT 134
4.14 SUPPLY CHAIN ANALYSIS 135
4.14.1 OVERVIEW 135
4.14.2 LOGISTIC COST SCENARIO 135
4.14.3 IMPORTANCE OF LOGISTICS SERVICE PROVIDERS 135
4.14.4 CONCLUSION 136
5 TARIFFS & IMPACT ON THE MARKET 137
5.1 OVERVIEW 137
5.2 CURRENT TARIFF RATE (S) IN TOP-5 COUNTRY MARKETS 137
5.3 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE 137
5.4 VENDOR SELECTION CRITERIA 138
5.5 IMPACT ON SUPPLY CHAIN 138
5.5.1 RAW MATERIAL PROCUREMENT 138
5.5.2 MANUFACTURING AND PRODUCTION 138
5.5.3 LOGISTICS AND DISTRIBUTION 138
5.5.4 PRICE PITCHING AND POSITION OF MARKET 138
5.6 INDUSTRY PARTICIPANTS: PROACTIVE MOVES 138
5.6.1 SUPPLY CHAIN OPTIMIZATION 138
5.6.2 JOINT VENTURE ESTABLISHMENTS 138
5.7 IMPACT ON PRICES 139
5.8 REGULATORY INCLINATION 139
5.8.1 GEOPOLITICAL SITUATION 139
5.8.2 TRADE PARTNERSHIPS BETWEEN THE COUNTRIES 139
5.8.2.1 FREE TRADE AGREEMENTS 139
5.8.2.2 ALLIANCES ESTABLISHMENTS 139
5.8.3 STATUS ACCREDITATION (INCLUDING MFTN) 139
5.8.4 DOMESTIC COURSE OF CORRECTION 139
5.8.4.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS 139
5.8.4.2 ESTABLISHMENT OF SEZS/INDUSTRIAL PARKS 139
6 REGULATION COVERAGE 140
6.1 PRODUCT CODES 140
6.2 CERTIFIED STANDARDS 140
6.3 SAFETY STANDARDS 141
6.3.1 MATERIAL HANDLING & STORAGE 141
6.3.2 TRANSPORT & PRECAUTIONS 141
6.3.3 HAZARD IDENTIFICATION 141
7 MARKET OVERVIEW 142
7.1 DRIVERS 144
7.1.1 RISE IN GASTROINTESTINAL BLEEDING CASES 144
7.1.2 AGING POPULATION DRIVING INCREASED DEMAND FOR GI DISORDERS 145
7.1.3 ADOPTION OF MINIMALLY INVASIVE ENDOSCOPIC PROCEDURES 146
7.1.4 RISING AWARENESS AND EXPANDED SCREENING PROGRAMS FOR GASTROINTESTINAL ENDOSCOPY 147
7.2 RESTRAINTS 148
7.2.1 HIGH COST AND TECHNICAL COMPLEXITY OF ENDOSCOPIC HEMOSTASIS DEVICES 148
7.2.2 LIMITED AWARENESS IN LOW-INCOME COUNTRIES 149
7.3 OPPORTUNITIES 150
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN HEMOSTASIS DEVICES 150
7.3.2 EXPANSION IN EMERGING MARKETS (ASIA-PACIFIC, LATIN AMERICA) 151
7.3.3 GROWING ADOPTION OF HOME-BASED AND CAPSULE ENDOSCOPY SOLUTIONS 152
7.4 CHALLENGES 153
7.4.1 REIMBURSEMENT ISSUES FOR ENDOSCOPIC PROCEDURES 153
7.4.2 COMPLEXITIES IN ENDOSCOPE REPROCESSING AND STERILIZATION PROCESSES 154
8 ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 155
8.1 OVERVIEW 156
8.2 MECHANICAL HEMOSTASIS DEVICES 159
8.2.1 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 159
8.2.1.1 HEMOSTATIC CLIPS 160
8.2.1.1.1 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE 160
8.2.1.1.1.1 THROUGH-THE-SCOPE (TTS) CLIPS 160
8.2.1.1.1.2 OVER-THE-SCOPE (OTS) CLIPS 160
8.2.1.1.2 HEMOSTATIC CLIPS IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY MATERIAL 161
8.2.1.1.2.1 STAINLESS STEEL 161
8.2.1.1.2.2 TITANIUM 161
8.2.1.2 BANDING DEVICES 162
8.2.1.2.1 BANDING DEVICES IN MECHANICAL HEMOSTASIS DEVICES MARKET, BY TYPE 162
8.2.1.2.1.1 VARICEAL BANDING KITS 162
8.2.1.2.1.2 OESOPHAGEAL BANDING DEVICES 162
8.2.1.3 HEMOSTATIC FORCEPS 162
8.2.1.4 OTHERS 162
8.2.2 MECHANICAL HEMOSTASIS DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 163
8.2.2.1 NORTH AMERICA 163
8.2.2.2 EUROPE 163
8.2.2.3 ASIA-PACIFIC 163
8.2.2.4 SOUTH AMERICA 163
8.2.2.5 MIDDLE EAST & AFRICA 163
8.3 THERMAL DEVICES 164
8.3.1 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 164
8.3.1.1 ARGON PLASMA COAGULATORS 164
8.3.1.2 HEATER PROBES 164
8.3.1.3 BIPOLAR COAGULATION DEVICES 164
8.3.1.3.1 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY ENERGY TYPE 165
8.3.1.3.1.1 MONOPOLAR 165
8.3.1.3.1.2 BIPOLAR 165
8.3.1.3.2 BIPOLAR COAGULATION IN THERMAL DEVICES MARKET, BY APPLICATION 166
8.3.1.3.2.1 UPPER GI BLEEDING 166
8.3.1.3.2.2 LOWER GI BLEEDING 166
8.3.1.4 OTHERS 166
8.3.2 THERMAL DEVICES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 167
8.3.2.1 NORTH AMERICA 167
8.3.2.2 EUROPE 167
8.3.2.3 ASIA-PACIFIC 167
8.3.2.4 SOUTH AMERICA 167
8.3.2.5 MIDDLE EAST & AFRICA 167
8.4 TOPICAL AGENTS AND INJECTABLES 168
8.4.1 TOPICAL AGENTS & INJECTIBLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 168
8.4.1.1 EPINEPHRINE INJECTION 168
8.4.1.2 HEMOSTATIC SPRAY (POWDER) 168
8.4.1.3 HEMOSTATIC GELS 168
8.4.1.4 FIBRIN SEALANTS 169
8.4.1.5 SCLEROSING AGENTS 169
8.4.2 TOPICAL AGENTS AND INJECTABLES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 169
8.4.2.1 NORTH AMERICA 169
8.4.2.2 EUROPE 169
8.4.2.3 ASIA-PACIFIC 169
8.4.2.4 SOUTH AMERICA 170
8.4.2.5 MIDDLE EAST & AFRICA 170
8.5 OTHERS 170
8.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 170
8.5.1.1 NORTH AMERICA 170
8.5.1.2 EUROPE 170
8.5.1.3 ASIA-PACIFIC 171
8.5.1.4 SOUTH AMERICA 171
8.5.1.5 MIDDLE EAST & AFRICA 171
9 ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET, BY PROCEDURE TYPE 172
9.1 OVERVIEW 173
9.2 UPPER GASTROINTESTINAL ENDOSCOPY 175
9.2.1 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 175
9.2.1.1 BLEEDING ULCER MANAGEMENT 176
9.2.1.2 VARICEAL BLEEDING 176
9.2.1.3 DIEULAFOY LESION 176
9.2.2 UPPER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 176
9.2.2.1 NORTH AMERICA 176
9.2.2.2 EUROPE 176
9.2.2.3 ASIA-PACIFIC 177
9.2.2.4 SOUTH AMERICA 177
9.2.2.5 MIDDLE EAST & AFRICA 177
9.3 LOWER GASTROINTESTINAL ENDOSCOPY 177
9.3.1 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 177
9.3.1.1 COLONIC BLEEDING 177
9.3.1.2 DIVERTICULAR BLEEDING 178
9.3.2 LOWER GASTROINTESTINAL ENDOSCOPY IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 178
9.3.2.1 NORTH AMERICA 178
9.3.2.2 EUROPE 178
9.3.2.3 ASIA-PACIFIC 178
9.3.2.4 SOUTH AMERICA 178
9.3.2.5 MIDDLE EAST & AFRICA 179
9.4 BRONCHOSCOPIC HEMOSTASIS 179
9.4.1 BRONCHOSCOPIC HEMOSTASIS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 179
9.4.1.1 NORTH AMERICA 179
9.4.1.2 EUROPE 179
9.4.1.3 ASIA-PACIFIC 179
9.4.1.4 SOUTH AMERICA 180
9.4.1.5 MIDDLE EAST & AFRICA 180
9.5 OTHERS 180
9.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 180
9.5.1.1 NORTH AMERICA 180
9.5.1.2 EUROPE 180
9.5.1.3 ASIA-PACIFIC 181
9.5.1.4 SOUTH AMERICA 181
9.5.1.5 MIDDLE EAST & AFRICA 181
10 ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET, BY APPLICATION 182
10.1 OVERVIEW 183
10.2 GASTROINTESTINAL BLEEDING 186
10.2.1 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 186
10.2.1.1 PEPTIC ULCER BLEEDING 187
10.2.1.2 ESOPHAGEAL VARICES 187
10.2.1.3 COLORECTAL CANCERS 187
10.2.2 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 187
10.2.2.1 MECHANICAL HEMOSTASIS DEVICES 187
10.2.2.2 THERMAL DEVICES 188
10.2.2.3 TOPICAL AGENTS AND INJECTABLES 188
10.2.2.4 OTHERS 188
10.2.3 GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 188
10.2.3.1 NORTH AMERICA 188
10.2.3.2 EUROPE 188
10.2.3.3 ASIA-PACIFIC 189
10.2.3.4 SOUTH AMERICA 189
10.2.3.5 MIDDLE EAST & AFRICA 189
10.3 NON-GASTROINTESTINAL BLEEDING 189
10.3.1 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 189
10.3.1.1 NASAL BLEEDING (EPISTAXIS) 189
10.3.1.2 POST-SURGICAL BLEEDING 190
10.3.2 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 190
10.3.2.1 MECHANICAL HEMOSTASIS DEVICES 190
10.3.2.2 THERMAL DEVICES 190
10.3.2.3 TOPICAL AGENTS & INJECTABLES 190
10.3.2.4 OTHERS 191
10.3.3 NON-GASTROINTESTINAL BLEEDING IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION, 2018-2033, (USD THOUSAND) 191
10.3.3.1 NORTH AMERICA 191
10.3.3.2 EUROPE 191
10.3.3.3 ASIA-PACIFIC 191
10.3.3.4 SOUTH AMERICA 191
10.3.3.5 MIDDLE EAST & AFRICA 192
10.4 TRAUMA MANAGEMENT 192
10.4.1 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY PRODUCT TYPE 192
10.4.1.1 MECHANICAL HEMOSTASIS DEVICES 192
10.4.1.2 THERMAL DEVICES 192
10.4.1.3 TOPICAL AGENTS & INJECTABLES 193
10.4.1.4 OTHERS 193
10.4.2 TRAUMA MANAGEMENT IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 193
10.4.2.1 NORTH AMERICA 193
10.4.2.2 EUROPE 193
10.4.2.3 ASIA-PACIFIC 193
10.4.2.4 SOUTH AMERICA 194
10.4.2.5 MIDDLE EAST & AFRICA 194
10.5 OTHERS 194
10.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 194
10.5.1.1 NORTH AMERICA 194
10.5.1.2 EUROPE 194
10.5.1.3 ASIA-PACIFIC 195
10.5.1.4 SOUTH AMERICA 195
10.5.1.5 MIDDLE EAST & AFRICA 195
11 ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET, BY END USER 196
11.1 OVERVIEW 197
11.2 HOSPITALS 200
11.2.1 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY TYPE 200
11.2.1.1 PUBLIC 200
11.2.1.2 PRIVATE 200
11.2.2 HOSPITALS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 201
11.2.2.1 NORTH AMERICA 201
11.2.2.2 EUROPE 201
11.2.2.3 ASIA-PACIFIC 201
11.2.2.4 SOUTH AMERICA 201
11.2.2.5 MIDDLE EAST & AFRICA 201
11.3 AMBULATORY SURGERY CENTERS 202
11.3.1 AMBULATORY SURGERY CENTERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 202
11.3.1.1 NORTH AMERICA 202
11.3.1.2 EUROPE 202
11.3.1.3 ASIA-PACIFIC 202
11.3.1.4 SOUTH AMERICA 202
11.3.1.5 MIDDLE EAST & AFRICA 203
11.4 SPECIALTY CLINICS 203
11.4.1 SPECIALTY CLINICS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 203
11.4.1.1 NORTH AMERICA 203
11.4.1.2 EUROPE 203
11.4.1.3 ASIA-PACIFIC 203
11.4.1.4 SOUTH AMERICA 204
11.4.1.5 MIDDLE EAST & AFRICA 204
11.5 OTHERS 204
11.5.1 OTHERS IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 204
11.5.1.1 NORTH AMERICA 204
11.5.1.2 EUROPE 204
11.5.1.3 ASIA-PACIFIC 205
11.5.1.4 SOUTH AMERICA 205
11.5.1.5 MIDDLE EAST & AFRICA 205
12 ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET, BY DISTRIBUTION CHANNEL 206
12.1 OVERVIEW 207
12.2 INDIRECT SALES 210
12.2.1 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS, BY TYPE 210
12.2.1.1 OFFLINE 210
12.2.1.2 ONLINE 210
12.2.2 INDIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 211
12.2.2.1 NORTH AMERICA 211
12.2.2.2 EUROPE 211
12.2.2.3 ASIA-PACIFIC 211
12.2.2.4 SOUTH AMERICA 211
12.2.2.5 MIDDLE EAST & AFRICA 211
12.3 DIRECT SALES 212
12.3.1 DIRECT SALES IN ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 212
12.3.1.1 NORTH AMERICA 212
12.3.1.2 EUROPE 212
12.3.1.3 ASIA-PACIFIC 212
12.3.1.4 SOUTH AMERICA 212
12.3.1.5 MIDDLE EAST & AFRICA 213
13 ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET, BY REGION 214
13.1 ASIA PACIFIC 216
13.1.1 CHINA 227
13.1.2 JAPAN 237
13.1.3 INDIA 247
13.1.4 SOUTH KOREA 257
13.1.5 AUSTRALIA 267
13.1.6 INDONESIA 277
13.1.7 THAILAND 287
13.1.8 MALAYSIA 297
13.1.9 SINGAPORE 307
13.1.10 PHILIPPINES 316
13.1.11 NEW ZEALAND 325
13.1.12 HONG KONG 334
13.1.13 TAIWAN 343
13.1.14 REST OF ASIA-PACIFIC 351
14 ASIA-PACIFIC ENDOSCOPIC HEMOSTASIS MARKET: COMPANY LANDSCAPE 360
14.1 COMPANY SHARE ANALYSIS: GLOBAL 360
15 SWOT ANALYSIS 361
16 COMPANY PROFILES MANUFACTURERS 362
16.1 OLYMPUS CORPORATION 362
16.1.1 COMPANY SNAPSHOT 362
16.1.2 REVENUE ANALYSIS 362
16.1.3 COMPANY SHARE ANALYSIS 363
16.1.4 PRODUCT PORTFOLIO 363
16.1.5 RECENT DEVELOPMENT 364
16.2 BOSTON SCIENTIFIC CORPORATION 365
16.2.1 COMPANY SNAPSHOT 365
16.2.2 REVENUE ANALYSIS 365
16.2.3 COMPANY SHARE ANALYSIS 366
16.2.4 PRODUCT PORTFOLIO 366
16.2.5 RECENT DEVELOPMENT 367
16.3 CONMED CORPORATION 368
16.3.1 COMPANY SNAPSHOT 368
16.3.2 REVENUE ANALYSIS 368
16.3.3 COMPANY SHARE ANALYSIS 369
16.3.4 PRODUCT PORTFOLIO 369
16.3.5 RECENT DEVELOPMENT 370
16.4 MEDTRONIC 371
16.4.1 COMPANY SNAPSHOT 371
16.4.2 REVENUE ANALYSIS 371
16.4.3 COMPANY SHARE ANALYSIS 372
16.4.4 PRODUCT PORTFOLIO 372
16.4.5 RECENT DEVELOPMENT 373
16.5 COOK 374
16.5.1 COMPANY SNAPSHOT 374
16.5.2 COMPANY SHARE ANALYSIS 374
16.5.3 PRODUCT PORTFOLIO 375
16.5.4 RECENT DEVELOPMENT 376
16.6 ANKAFERD 377
16.6.1 COMPANY SNAPSHOT 377
16.6.2 PRODUCT PORTFOLIO 377
16.6.3 RECENT DEVEOPMENT 378
16.7 B. BRAUN SE 379
16.7.1 COMPANY SNAPSHOT 379
16.7.2 PRODUCT PORTFOLIO 379
16.7.3 RECENT DEVEOPMENT 379
16.8 CREO MEDICAL GMBH 380
16.8.1 COMPANY SNAPSHOT 380
16.8.2 PRODUCT PORTFOLIO 380
16.8.3 RECENT DEVELOPMENT 380
16.9 DIVERSATEK, INC. 381
16.9.1 COMPANY SNAPSHOT 381
16.9.2 PRODUCT PORTFOLIO 381
16.9.3 RECENT DEVEOPMENT 381
16.10 DUOMED GROUP 382
16.10.1 COMPANY SNAPSHOT 382
16.10.2 PRODUCT PORTFOLIO 382
16.10.3 RECENT DEVEOPMENT 383
16.11 ENDOCLOT PLUS, INC. 384
16.11.1 COMPANY SNAPSHOT 384
16.11.2 PRODUCT PORTFOLIO 384
16.11.3 RECENT DEVEOPMENT 385
16.12 ERBE ELEKTROMEDIZIN GMBH 386
16.12.1 COMPANY SNAPSHOT 386
16.12.2 PRODUCT PORTFOLIO 386
16.12.3 RECENT DEVELOPMENT 387
16.13 FUJIFILM HOLDINGS CORPORATION 388
16.13.1 COMPANY SNAPSHOT 388
16.13.2 REVENUE ANALYSIS 388
16.13.3 PRODUCT PORTFOLIO 389
16.13.4 RECENT DEVELOPMENT 393
16.14 JOHNSON & JOHNSON (ETHICON) 394
16.14.1 COMPANY SNAPSHOT 394
16.14.2 REVENUE ANALYSIS 394
16.14.3 PRODUCT PORTFOLIO 395
16.14.4 RECENT DEVEOPMENT 396
16.15 KARL STORZ SE & CO. KG, TUTTLINGEN 397
16.15.1 COMPANY SNAPSHOT 397
16.15.2 PRODUCT PORTFOLIO 397
16.15.3 RECENT DEVEOPMENT 397
16.16 MEDITALIA S.R.L. 398
16.16.1 COMPANY SNAPSHOT 398
16.16.2 PRODUCT PORTFOLIO 398
16.16.3 RECENT DEVELOPMENT 399
16.17 MICRO-TECH ENDOSCOPY 400
16.17.1 COMPANY SNAPSHOT 400
16.17.2 PRODUCT PORTFOLIO 400
16.17.3 RECENT DEVELOPMENT 401
16.18 MTW ENDOSKOPIE MANUFAKTU 402
16.18.1 COMPANY SNAPSHOT 402
16.18.2 PRODUCT PORTFOLIO 402
16.18.3 RECENT DEVEOPMENT 402
16.19 OVESCO ENDOSCOPY AG 403
16.19.1 COMPANY SNAPSHOT 403
16.19.2 PRODUCT PORTFOLIO 403
16.19.3 RECENT DEVEOPMENT 404
16.20 PENTAX MEDICAL 405
16.20.1 COMPANY SNAPSHOT 405
16.20.2 SOLUTION PORTFOLIO 405
16.20.3 RECENT DEVELOPMENT 405
16.21 STERIS 406
16.21.1 COMPANY SNAPSHOT 406
16.21.2 REVENUE ANALYSIS 406
16.21.3 PRODUCT PORTFOLIO 407
16.21.4 RECENT DEVELOPMENT 410
17 COMPANY PROFILES DISTRIBUTOR 411
17.1 BOSTON IVY HEALTHCARE SOLUTIONS PRIVATE LIMITED 411
17.1.1 COMPANY SNAPSHOT 411
17.1.2 PRODUCT PORTFOLIO 411
17.1.3 RECENT DEVELOPMENT 411
17.2 CARDINAL HEALTH 412
17.2.1 COMPANY SNAPSHOT 412
17.2.2 REVENUE ANALYSIS 412
17.2.3 PRODUCT PORTFOLIO 413
17.2.4 RECENT DEVEOPMENT 413
17.3 HENRY SCHEIN, INC. 414
17.3.1 COMPANY SNAPSHOT 414
17.3.2 REVENUE ANALYSIS 414
17.3.3 PRODUCT PORTFOLIO 415
17.3.4 RECENT DEVEOPMENT 415
17.4 MCKESSON MEDICAL-SURGICAL INC. 416
17.4.1 COMPANY SNAPSHOT 416
17.4.2 PRODUCT PORTFOLIO 416
17.4.3 RECENT DEVEOPMENT 417
17.5 MFI MEDICAL 418
17.5.1 COMPANY SNAPSHOT 418
17.5.2 PRODUCT PORTFOLIO 418
17.5.3 RECENT DEVEOPMENT 418
18 QUESTIONNAIRE 419
19 RELATED REPORTS 422
?